Clinical impact of EUCAST rapid antimicrobial susceptibility testing on empirical therapy in bloodstream infections: a real-world observational study - Takeaways - MDSpire

Clinical impact of EUCAST rapid antimicrobial susceptibility testing on empirical therapy in bloodstream infections: a real-world observational study

  • By

  • Lukas Schaffarczyk

  • Patricia Carla Mayer

  • Axel Hamprecht

  • Philipp Thelen

  • May 18, 2026

  • 0 min

Share

  • 1

    The study evaluates the impact of EUCAST Rapid Antimicrobial Susceptibility Testing (RAST) on empirical treatment duration in bloodstream infections.

  • 2

    RAST provides rapid susceptibility results from positive blood cultures, significantly improving diagnostic turnaround times.

  • 3

    The study focuses on gram-negative pathogens, including E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii.

  • 4

    Results indicate that RAST may lead to earlier adjustments in antimicrobial therapy based on susceptibility findings.

  • 5

    The study highlights the importance of timely antimicrobial therapy in reducing morbidity and mortality associated with bloodstream infections.

Original Source(s)

Clinical impact of EUCAST rapid antimicrobial susceptibility testing on empirical therapy in bloodstream infections: a real-world observational study

  • by Lukas Schaffarczyk, Patricia Carla Mayer, Axel Hamprecht, Philipp Thelen

  • May 18, 2026

Related Content

Severe cutaneous anthrax with systemic complications: a case report

Pharmacological intervention of the HMGB1-pCTS-L axis to ameliorate inflammatory diseases

Computational discovery of PGD, MAPK14, and KRAS as diagnostic biomarkers for neonatal sepsis through integrated machine learning, immune infiltration analysis, and molecular docking